Pathos AI secures $237M Series E funding at $3B valuation, partners with Bristol Myers on neuroscience
read at Endpoints ↗DealPositive
Pathos AI, an AI-focused biotech based in New York, announced it has closed a Series E financing round raising $237 million.
The round values the company at $3 billion, reflecting investor confidence in its AI-driven drug discovery platform.
As part of the financing, Pathos entered a partnership with Bristol Myers Squibb to collaborate on neuroscience programs.
The collaboration aims to combine Pathos's computational tools with Bristol Myers' expertise to accelerate development of treatments for neurological disorders.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership”
read at Endpoints ↗87 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that